trending Market Intelligence /marketintelligence/en/news-insights/trending/kpvbwtuzlvp_e96p_-4uhw2 content esgSubNav
In This List

Kezar Life Sciences plans $80.5M IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Kezar Life Sciences plans $80.5M IPO

Kezar Life Sciences Inc. is planning an IPO of up to $80.5 million of its ordinary shares on the Nasdaq Global Market.

The South San Francisco, Calif.-based biotechnology company, which plans to list under the trading symbol KZR, intends to use the proceeds to fund the development of its lead product candidate KZR-616 as a potential treatment of multiple autoimmune and inflammatory diseases.

Jefferies and Cowen are acting as lead book-running managers for the IPO, and Wells Fargo Securities and William Blair are acting as the joint book-running managers.